Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 736 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis
Jieruo Gu¹, Liudan Tu², Minjing Zhao³, Zhiming Lin⁴, Zetao Liao⁵, Shuangyan Cao⁶, Qinghong Yu⁷ and Zhizhong Ye⁸, ¹Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ²The Third Hospital of Sun Yat-sen University, Guangzhou, China, ³The Third Affiliated Hospital of Sun Yat-sen University, guangzhou, China, ⁴Rheumatology, 3rd Affiliated Hospital of Sun Yat-Sen Uni, Guangzhou, China, ⁵Rheumatology, 3rd Affiliated Hoapital of Sun Yat-Sen Uni, Guangzhou, China, ⁶Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ⁷Department of Rheumatology, Fourth People’s Hospital of Shenzhen City, Xiangmi Lake branch, Guangzhou, China, ⁸Department of Rheumatology，ZhuJiang Hospital of Southern Medical University, Guangzhou, China
Background/Purpose: To compare the clinical、radiographic and magnatic resonance imaging change in active ankylosing spondylitis patients with etanercept and celecoxib alone/combined treatment，and to evaluate the effectiveness…
Abstract Number: 1676 • 2016 ACR/ARHP Annual Meeting
Methotrexate and Anti-Tumor Necrosis Treatment Improve Endothelial Function in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gia Deyab¹, Ingrid Hokstad², Stefan Agewall³, Torstein Lyberg⁴, Jon Elling Whist⁵, Milada Cvancarova Småstuen⁶, Gunnbjørg Hjeltnes⁷ and Ivana Hollan^8,9,10,11, ¹Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, ²Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, ³University of Oslo, Oslo, Norway, ⁴Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁵Innlandet Hospital Trust, Lillehammer, Norway, ⁶Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, ⁷Medicine, Innlandet Hospital Trust, Lillehammer, Norway, ⁸Harvard Medical School, Boston, MA, ⁹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ¹⁰Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹¹Innlandet Hospital Trust, Brumunddal, Norway
Background/Purpose: Inflammatory rheumatic diseases (IRDs) are associated with accelerated atherosclerosis, which progression is related to inflammation (1). One of the first stages in atherogenesis is…
Abstract Number: 2715 • 2016 ACR/ARHP Annual Meeting
Genetic Variants in TNF, TNFRSF1A, and IL23R Are Associated with Risk of Ankylosing Spondylitis
Jacob Sode^1,2,3, Ulla Vogel⁴, Steffen Bank⁵, Paal Skytt Andersen⁶, Merete Lund Hetland⁷, Henning Locht², Niels H. H. Heegaard⁸ and Vibeke Andersen⁹, ¹Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ²Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, ³Department of Rheumatology, Skåne University Hospital, Lund, Sweden, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark, ⁵Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, ⁶Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, ⁷DANBIO Registry and Departments of Rheumatology, Rigshospitalet (Glostrup and Blegdamsvej), University of Copenhagen, Glostrup, Denmark, ⁸Department of Autoimmunology & Biomarkers, Statens Serum Institut, Copenhagen, Denmark, ⁹Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark
Background/Purpose: The objective of this study was to evaluate single nucleotide polymorphisms (SNPs) involved in TNFα signaling, NF-κB activation, interferon-γ signaling, or pattern recognition receptor…
Abstract Number: 686 • 2016 ACR/ARHP Annual Meeting
Development and Evaluation of the Combined Ankylosing Spondylitis Spine Score (CASSS) for the Assessment of Spinal Radiographic Outcome
Fiona Maas¹, Anneke Spoorenberg^1,2, Elisabeth Brouwer¹, Hendrika Bootsma³, Reinhard Bos², Freke Wink² and Suzanne Arends^1,2, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: Spinal radiographic progression is a highly variable process in ankylosing spondylitis (AS). Our aim was to develop a combined AS spine score (CASSS) in…
Abstract Number: 910 • 2016 ACR/ARHP Annual Meeting
Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study
Amar Oza¹, Na Lu² and Hyon K. Choi³, ¹Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Boston, MA, ²Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ³Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of…
Abstract Number: 1728 • 2016 ACR/ARHP Annual Meeting
Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease
Mehmet Ali Balci¹, Mustafa Ferhat Oksuz², Salim Donmez¹, Tugce Ozen³, Ediz Dalkilic², Ayse Nur Tufan², Yavuz Pehlivan² and Omer Nuri Pamuk⁴, ¹Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, ²Rheumatology, Uludag University Medcal Faculty, Bursa, Turkey, ³PHYSICAL THERAPY AND REHABILITATION, Trakya University Faculty of Health Sciences, Edirne, Turkey, ⁴Rheumatology, Department of Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, Edirne, Turkey
Background/Purpose: Psoriatic arthritis (PsA), Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are an inflammatory arthritis causing joint damage and disability. Non-adherence to disease modifying anti-rheumatic…
Abstract Number: 2736 • 2016 ACR/ARHP Annual Meeting
Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?
Marina N. Magrey¹, Sherilyn Diomampo² and Muhammad Asim Khan³, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²MetroHealth Medical Center, Cleveland, OH, ³Medicine/ Rheumatology, Case Western Reserve Univ, Cleveland, OH
Background/Purpose: Concomitant fibromyalgia syndrome (FMS) is a common problem in ankylosing spondylitis (AS) and its recognition is important for optimal management. BASDAI, a disease activity…
Abstract Number: 687 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Atul A. Deodhar¹, Maxime Dougados², Robert Landewé³, Joachim Sieper⁴, Walter Maksymowych⁵, Martin Rudwaleit⁶, Filip van Den Bosch⁷, Jürgen Braun⁸, Philip J Mease⁹, Alan Kivitz¹⁰, Jessica Walsh¹¹, Owen Davies¹², Bengt Hoepken¹³, Luke Peterson¹⁴ and Désirée van der Heijde¹⁵, ¹Divison of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Academic Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, Netherlands, ⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Klinikum Bielefeld and Charité – University Medicine Berlin, Berlin, Germany, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰Altoona Center for Clinical Research, Duncansville, PA, ¹¹Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Monheim, Germany, ¹⁴UCB Pharma, Raleigh, NC, ¹⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RAPID-axSpA (NCT01087762) investigated the efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non-radiographic…
Abstract Number: 962 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Atul A. Deodhar¹, Stefan Schreiber², Kunal Gandhi³, Todd Fox⁴, Corine Gaillez⁴ and Chetan Karyekar³, ¹Oregon Health & Science University, Portland, OR, ²Christian-Albrechts-Universität Kiel, Kiel, Germany, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has been evaluated and approved for the treatment of moderate to severe psoriasis, active psoriatic arthritis (PsA)…
Abstract Number: 1739 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Secukinumab and Adalimumab in Ankylosing Spondylitis As Assessed By Matching-Adjusted Indirect Comparison: An Analysis Based on All Pivotal Phase 3 Clinical Trial Data
Walter P Maksymowych¹, Vibeke Strand², Peter Nash³, Howard Thom⁴, Andreas Karabis⁵, Kunal Gandhi⁶, Brian Porter⁶ and Steffen Jugl⁷, ¹University of Alberta, Edmonton, AL, ²Stanford University School of Medicine, Palo Alto, CA, ³Department of Medicine, University of Queensland, Brisbane, QLD, Australia, ⁴University of Bristol, Bristol, United Kingdom, ⁵MAPI Group, Houten, Netherlands, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) and adalimumab (ADA) are approved for the treatment of patients with active AS. However, there are no head-to-head randomized controlled trials (RCTs)…
Abstract Number: 2755 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Profile of Geriatric and Non-Geriatric Ankylosing Spondylitis (AS) Patients
Ahmed Omar¹, Laura Passalent², Renise Ayearst³, Ismail Sari¹, Anthony V. Perruccio⁴, Rajiv Gandhi⁵, Nigil Haroon¹ and Robert D Inman¹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Allied Health, Toronto Western Hospital, Toronto, ON, Canada, ³Medicine, University Health Network, Toronto, ON, Canada, ⁴Health Care & Outcomes Research, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁵Department of Surgery - Orthopedics, Toronto Western Hospital, Assistant Professor, Department of Surgery, University of Toronto, Toronto, ON, Canada
Background/Purpose: Data on disease characteristics of geriatric patients (>=65 years) with AS are lacking. The objective of this study is to compare: 1) the clinical…
Abstract Number: 695 • 2016 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Randomized Placebo-Controlled Trial
Xenofon Baraliakos¹, Michael Schiff², Karel Pavelka³, Ruvie Martin⁴, Brian Porter⁴ and Corine Gaillez⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²University of Colorado, School of Medicine, Denver, CO, ³Institute and Cliníc of Rheumatology, Charles University, Prague, Czech Republic, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The assessment of achieving, maintaining, and improving clinical response to biologics in Ankylosing Spondylitis (AS) is part of treat-to-target recommendations aimed at optimizing treatment…
Abstract Number: 1044 • 2016 ACR/ARHP Annual Meeting
Treatment with Tofacitinib Is Associated with Clinically Meaningful Reductions in Axial MRI Inflammation in Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Désirée van der Heijde², Xenofon Baraliakos³, Atul A. Deodhar⁴, Matt Brown⁵, Sarah Sherlock⁶, David Li⁷, Dona Fleishaker⁸ and Thijs Hendrikx⁷, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ⁵Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia, ⁶Pfizer Inc, Cambridge, MA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor. Minimum clinically important differences (MCID) for SPondyloArthritis Research Consortium of Canada (SPARCC) MRI SI joint and spine…
Abstract Number: 1916 • 2016 ACR/ARHP Annual Meeting
Heightened MAIT Cell Sensitivity to MR1 Ligands Could Impact Control of Dysbiosis in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Diahann Jansen¹, Elizabeth Klinken¹, Hendrik Nel², Soi Cheng Law², Helen Benham^3,4,5, Lisa Cummins⁶, Matthew Brown⁷, Tony Kenna², Ligong Liu⁸, David Fairlie⁸, Jamie Rossjohn^9,10,11, Mark Morrison³, Ranjeny Thomas³, Paraic O Cuiv¹, James McCluskey¹² and Alexandra Corbett¹², ¹The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Australia, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³Translational Research Institute, The University of Queensland Diamantina Institute, Woolloongabba, Australia, ⁴University of Queensland School of Medicine, Brisbane, Australia, ⁵Rheumatology, Princess Alexandra Hospital, Woolloongabba, Australia, ⁶Princess Alexandra Hospital, Woolloongabba, Australia, ⁷Queensland University of Technology, Brisbane, Australia, ⁸Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia, ⁹Infection and Immunity Program, Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia, ¹⁰Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ¹¹Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Australia, ¹²Department of Microbiology & Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia
Background/Purpose: Mucosal associated invariant T (MAIT) cells are an innate-like lymphocyte population predominant at mucosal sites, which express a semi-invariant T cell receptor restricted to…
Abstract Number: 2756 • 2016 ACR/ARHP Annual Meeting
Gender Differences in Body Composition with Dual-Energy X-Ray Absorptiometry in TNF-α Blocker Naive Ankylosing Spondylitis Patients
Sebastián Ibáñez^1,2, Ingrid M. Visman³, Christiaan van Denderen³, Willem F. Lems^4,5, M. Nurmohamed^4,6 and Irene van der Horst - Bruinsma⁴, ¹Reumatología, Clínica Alemana de Santiago, Santiago, Chile, ²Reumatología, Hospital Padre Hurtado, Santiago, Chile, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, New Caledonia, ⁶Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands
Background/Purpose: Data on body composition (BC) in Ankylosing Spondylitis (AS) are sparse and controversial. Female AS patients have less response to TNF-α blockers and a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].